News

Following an appeal the drug will now be available to treat ALL

Takeda has committed $100 million, including the participation in the Series A financing, to Ambys

Lawsuits allege that the company falsely and misleadingly marketed the two drugs

Diabetes segment stumbles but key brand report solid performance

British Biosimilars Association say the proposals “make no sense”

Iain will join the company on 14 Janurary 2019 and will also be appointed as an Executive Director to the Board

Agency expects close cooperation with EU and for the new Clinical Trials Regulation to apply in UK

Companies will investigate targets that historically have been a challenge for therapeutic development

Companies will leverage each others technology platforms against six initial targets

Collaboration also includes UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations, and Oxford BioMedica

Offering a professional training and development day aimed at improving performance and real world results, companies that support their teams through the all new PharmaTimes Sales Awards will, by demonstrating a desire to encourage learning and development, attract new talent to their organisation and create affiliate pride. “Shining a light on the professionalism of your team, overall success in the competition will also impact positively on your brand and its position in the marketplace,” says PharmaTimes business manager and competition lead Luci Sargood.

For the first time ever, the Communications Team of the Year competition will give individuals in agencies and pharma companies the chance to compete side by side.

PharmaTimes talks to Jayne Packham, managing director of the Jayne Packham Consultancy and lead judge for the Medical Information categories, about the importance of the new, PharmaTimes Medical & Scientific Excellence Awards.

RG6042 could be the first therapy targeting the underlying cause of the disease

RG6042 could be the first therapy targeting the underlying cause of the disease